Department of Otorhinolaryngology and Maxillofacial Surgery, Medical Faculty, University of Osijek, J. Huttlera 4, 31000 Osijek, Croatia.
Department of Otorhinolaryngology and Head and Neck Surgery, Clinical Hospital Centre Osijek, J. Huttlera 4, 31000 Osijek, Croatia.
Diving Hyperb Med. 2022 Sep 30;52(3):191-196. doi: 10.28920/dhm52.3.191-196.
Previous studies suggest the effectiveness of hyperbaric oxygen treatment (HBOT) in idiopathic sudden sensorineural hearing loss (ISSNHL) but it is mostly used as an adjuvant and salvage treatment. This study evaluated the effect of primary HBOT according to pretreatment hearing grades and hearing recovery outcomes using modified Siegel's criteria in patients with ISSNHL.
Fifty-nine ISSNHL patients treated with only HBOT were included. A pure-tone audiogram was recorded before and after a course of HBOT (90 min at 203 kPa daily for 20 days). Using the modified Siegel's criteria, patients were divided into groups according to hearing threshold before and after treatment.
Hearing thresholds were significantly lower after HBOT compared to pre-treatment values across all patients (P < 0.001) with a median value of recovery of 22.5 dB (interquartile range 12.5-33.7 dB). Significantly lower hearing threshold values were recorded at 500, 1,000, 2,000, and 4,000 Hz after treatment (P < 0.001). The greatest recovery was at 1,000 Hz, (change in median threshold = 32 dB) but without a significant difference compared to other frequencies (P = 0.10).
HBOT is a legitimate choice as the primary treatment for ISSNHL, especially if it is readily accessible, and if there are contraindications for corticosteroid therapy.
先前的研究表明高压氧治疗(HBOT)在特发性突发性聋(ISSNHL)中的有效性,但它主要用作辅助和挽救治疗。本研究根据预处理听力等级和使用 Siegel 标准改良版评估 ISSNHL 患者接受原发性 HBOT 的效果。
59 例仅接受 HBOT 治疗的 ISSNHL 患者纳入本研究。在接受 90 分钟 203 kPa 每日 1 次的 20 天疗程的 HBOT 前后记录纯音听力图。使用 Siegel 标准改良版,根据治疗前后的听力阈值将患者分为不同组。
与治疗前相比,所有患者的 HBOT 后听力阈值均显著降低(P<0.001),中位数恢复值为 22.5dB(四分位间距 12.5-33.7dB)。治疗后,500、1000、2000 和 4000Hz 的听力阈值显著降低(P<0.001)。1000Hz 的恢复最大(中位数阈值变化=32dB),但与其他频率相比无显著差异(P=0.10)。
HBOT 是 ISSNHL 的一种合理的初始治疗选择,尤其是如果 HBOT 易于获得且存在皮质类固醇治疗禁忌证时。